Valuation: Amicus Therapeutics, Inc.

Market Cap 4.55B 4B 3.72B 3.42B 6.41B 441B 6.53B 44.45B 17.34B 215B 17.08B 16.71B 746B P/E 2024
-51.1x
P/E 2025 -162x
Enterprise Value 4.7B 4.13B 3.84B 3.53B 6.62B 455B 6.74B 45.91B 17.91B 222B 17.64B 17.26B 770B EV / Sales 2024
5.69x
EV / Sales 2025 7.18x
Free-Float
99.31%
Yield 2024 *
-
Yield 2025 -
1 day+0.21%
3 months+0.21%
6 months+1.54%
Current year+1.76%
Current year 14.2
Extreme 14.205
14.5
1 year 5.92
Extreme 5.925
14.5
3 years 5.51
Extreme 5.51
14.57
5 years 5.51
Extreme 5.51
14.57
10 years 4.41
Extreme 4.41
25.39
Date Insider Type Main position Quantity % Market Cap.
27/4/26 Issuer sale

General Counsel

1,264,993 0.4029%
27/4/26 Issuer sale

Director

398,261 0.1268%
27/4/26 Issuer sale

Director

446,194 0.1421%
Change 5-day change 1-year change 3-year change Capi.($)
+0.21%-.--%+129.64%+6.15% 4.55B
+1.08%-5.74%-4.98%+10.45% 46.06B
+3.13%+5.34%+402.93%+605.08% 38.91B
+2.14%+2.95%+10.83%+65.45% 35.57B
+4.43%-1.51%+6.73%-9.17% 33.13B
+1.23%-2.05%+0.56%+30.76% 26.42B
+0.29%-2.75% - - 16.61B
+14.71%+12.62%+38.50%+146.99% 15.08B
-6.32%-4.86%+4.36%+8.22% 14.08B
+1.82%+0.19%+1.45%-30.74% 12.81B
Average +2.12%-0.37%+65.56%+92.58% 24.32B
Weighted average by Cap. +2.19%-1.26%+76.44%+127.22%

Financials

2024 2025
Net sales 528M 465M 432M 397M 744M 51.16B 758M 5.16B 2.01B 24.95B 1.98B 1.94B 86.57B 634M 558M 518M 477M 894M 61.42B 910M 6.2B 2.42B 29.96B 2.38B 2.33B 104B
Net income -56.11M -49.35M -45.84M -42.16M -79.07M -5.43B -80.48M -548M -214M -2.65B -211M -206M -9.19B -27.11M -23.84M -22.15M -20.37M -38.2M -2.63B -38.89M -265M -103M -1.28B -102M -99.58M -4.44B
Net Debt 194M 170M 158M 146M 273M 18.76B 278M 1.89B 738M 9.15B 727M 711M 31.74B 149M 131M 122M 112M 210M 14.41B 213M 1.45B 567M 7.03B 559M 547M 24.39B
Logo Amicus Therapeutics, Inc.
Amicus Therapeutics, Inc. is a global biotechnology company focused on discovering, developing and delivering medicines for people living with rare diseases. Its two marketed therapies are Galafold, the first oral monotherapy for people living with Fabry disease who have amenable genetic variants, and Pombiliti + Opfolda, a two-component treatment for adults living with late-onset Pompe disease. As an orally miglustat monotherapy, Galafold is designed to bind to and stabilize an endogenous alpha-galactosidase A enzyme in those patients with genetic variants identified as amenable in a Good Laboratory Practice cell-based amenability assay. Pombiliti + Opfolda consists of an engineered rhGAA enzyme, cipaglucosidase alfa-atga, with an optimized carbohydrate structure to enhance cellular uptake, administered intravenously in combination with orally administered miglustat. In addition, clinical studies are ongoing in pediatric patients for both the LOPD and IOPD populations.
Employees
511
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B
  1. Stock Market
  2. Stocks
  3. FOLD Stock